A Randomized, Multicenter, Phase III Trial of Tacrolimus/Methotrexate/Ruxolitinib versus PostTransplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation

Disease Sites:

Leukemia, Lymphoma

Staging:

Phase III

Age Group:

Adults

Therapies:

Chemotherapy - cytotoxic, Mol. targeted/Immunotherapy/Biologics

Drugs:

Cyclophosphamide, Methotrexate, Mycophenolate Mofetil (MMF), Ruxolitinib, Tacrolimus

Principal Investigator(s):

Dholaria, Bhagirathbhai

Scope:

National

Participating Institutions:

Vanderbilt University

Open Date:

09-12-2025

Trial Type:

Treatment

Protocol ID:

VICC-DTCTT23454

National Clinical Trial ID:

NCT06615050

Eligibility

Ages Eligible for Study:

Not Available

Genders Eligible for Study:

Not Available

Accepts Healthy Volunteers?:

Not Available